Skip to main content

Cancer Chemotherapy and Pharmacology

Ausgabe 1/2014

Inhalt (25 Artikel)

Open Access Review Article

Mechanisms of action of tasquinimod on the tumour microenvironment

E. Raymond, A. Dalgleish, J.-E. Damber, M. Smith, R. Pili

Original Article

A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)

Yoshihiro Hattori, Miyako Satouchi, Nobuyuki Katakami, Shiro Fujita, Reiko Kaji, Akito Hata, Yoshiko Urata, Temiko Shimada, Junji Uchida, Keisuke Tomii, Satoshi Morita, Shunichi Negoro

Original Article

Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice

Hue Jung Park, Jennifer A. Stokes, Maripat Corr, Tony L. Yaksh

Original Article

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma

Sheeba K. Thomas, Alexander Suvorov, Lucien Noens, Oleg Rukavitsin, Joseph Fay, Ka Lung Wu, Todd M. Zimmerman, Helgi van de Velde, Rajesh Bandekar, Thomas A. Puchalski, Ming Qi, Clarissa Uhlar, Olga S. Samoylova

Original Article

Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients

Jan Nyrop Jakobsen, Eric Santoni-Rugiu, Jens Benn Sørensen

Original Article

Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma

Hitoshi Ando, Atsushi Natsume, Takeshi Senga, Reiko Watanabe, Ichiro Ito, Masasuke Ohno, Kenichiro Iwami, Fumiharu Ohka, Kazuya Motomura, Sayano Kinjo, Maki Ito, Kiyoshi Saito, Richard Morgan, Toshishiko Wakabayashi

Original Article

Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study

Anne Floquet, Adélaïde Doussau, Véronique Brouste, Laurent Cany, Jean-Philippe Dutin, Simone Mathoulin-Pélissier

Original Article

Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production

Lei Gong, Bo Yang, Ming Xu, Bo Cheng, Xuejun Tang, Ping Zheng, Yan Jing, Gao-jue Wu

Original Article

Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies

Wei-qun Xu, Ling-yan Zhang, Xue-ying Chen, Bin-hua Pan, Jun-qing Mao, Hua Song, Jing-yuang Li, Yong-min Tang

Original Article

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer

D. de Wit, H. Gelderblom, A. Sparreboom, J. den Hartigh, M. den Hollander, J. M. C. König-Quartel, T. Hessing, H. J. Guchelaar, N. P. van Erp

Original Article

Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer

Hiroki Yamaue, Sohei Satoi, Takamasa Kanbe, Motoki Miyazawa, Masaji Tani, Manabu Kawai, Seiko Hirono, Kenichi Okada, Hiroaki Yanagimoto, A-Hon Kwon, Tomoyuki Mukouyama, Hiroaki Tsunoda, Kazuo Chijiiwa, Jiro Ohuchida, Jun Kato, Kazuki Ueda, Taketo Yamaguchi, Shinichi Egawa, Kazuhiko Hayashi, Tetsuhiko Shirasaka

Original Article

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

J. F. Grippo, W. Zhang, D. Heinzmann, K. H. Yang, J. Wong, A. K. Joe, P. Munster, N. Sarapa, A. Daud

Original Article

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

M. Joerger, A. D. R. Huitema, D. Koeberle, H. Rosing, J. H. Beijnen, F. Hitz, T. Cerny, J. H. M. Schellens, S. Gillessen

Original Article

Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients

Jung Yong Hong, Eun Mi Nam, Jeeyun Lee, Joon Oh Park, Sang-Cheol Lee, Seo-Young Song, Seong Ho Choi, Jin Seok Heo, Se Hoon Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park

Original Article

Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer

Jan Nyrop Jakobsen, Eric Santoni-Rugiu, Jens Benn Sørensen

Original Article

Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101)

Yoon-Koo Kang, Jeong Hwan Yook, Heung-Moon Chang, Min-Hee Ryu, Changhoon Yoo, Dae Young Zang, Jae-Lyun Lee, Tae Won Kim, Dae Hyun Yang, Se Jin Jang, Young Soo Park, Young Jack Lee, Hwoon-Yong Jung, Jin-Ho Kim, Byung Sik Kim

Open Access Original Article

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, Gary R. Hudes, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Sindy T. Kim, Xin Huang, J. Andrew Williams, Tim Eisen, Robert J. Motzer

Original Article

A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer

Young Saing Kim, Sun Jin Sym, Se Hoon Park, Inkeun Park, Junshik Hong, Hee Kyung Ahn, Jinny Park, Eun Kyung Cho, Woon Ki Lee, Min Chung, Jae Hoon Lee, Dong Bok Shin

Original Article

E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer

Taofeek K. Owonikoko, Joseph Aisner, Xin Victoria Wang, Suzanne E. Dahlberg, Eric H. Rubin, Suresh S. Ramalingam, Murugesan Gounder, Paul Gregory Rausch, Rita S. Axelrod, Joan H. Schiller

Open Access Original Article

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Ana M. Molina, Thomas E. Hutson, James Larkin, Anne M. Gold, Karen Wood, Dave Carter, Robert Motzer, M. Dror Michaelson

Original Article

Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer

Seung Woo Yi, Dae Ryong Kang, Kyung Sik Kim, Mi Suk Park, Jinsil Seong, Jeong Youp Park, Seung Min Bang, Si Young Song, Jae Bock Chung, Seung Woo Park

Original Article

The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma

Chih-Jen Yang, Ying-Ming Tsai, Ming-Ju Tsai, Hsu-Liang Chang, Ming-Shyan Huang

Short Communication

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers

Hussein Tawbi, Susan M. Christner, Yan Lin, Matthew Johnson, Emily T. Mowrey, Craig Cherrin, Edward Chu, James J. Lee, Shannon Puhalla, Ronald Stoller, Leonard R. Appleman, Brian M. Miller, Jan H. Beumer

Open Access Short Communication

Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors

Yi-Lin Chiu, Patricia LoRusso, Balakrishna Hosmane, Justin L. Ricker, Walid Awni, Dawn M. Carlson

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.